Abivax Net Income From Continuing Ops from 2010 to 2026

ABVX Stock   119.78  2.11  1.79%   
Abivax SA Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2026. During the period from 2010 to 2026, Abivax SA Net Loss regression line of annual values had significance of  0.0002 and arithmetic mean of (64,021,924). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-158.6 M
Current Value
-150.7 M
Quarterly Volatility
55 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Abivax SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abivax SA's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 3 M or Selling General Administrative of 39.8 M, as well as many indicators such as Price To Sales Ratio of 33.77, Dividend Yield of 0.0 or PTB Ratio of 7.67. Abivax financial statements analysis is a perfect complement when working with Abivax SA Valuation or Volatility modules.
  
Build AI portfolio with Abivax Stock
Check out the analysis of Abivax SA Correlation against competitors.
The evolution of Net Income From Continuing Ops for Abivax SA American provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Abivax SA compares to historical norms and industry peers.

Latest Abivax SA's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Abivax SA American over the last few years. It is Abivax SA's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abivax SA's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Abivax Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(64,021,924)
Coefficient Of Variation(85.96)
Mean Deviation45,061,658
Median(30,633,000)
Standard Deviation55,032,803
Sample Variance3028.6T
Range145.6M
R-Value(0.79)
Mean Square Error1207.8T
R-Squared0.63
Significance0.0002
Slope(8,623,480)
Total Sum of Squares48457.8T

Abivax Net Income From Continuing Ops History

2026-150.7 M
2025-158.6 M
2024-176.2 M
2023-147.7 M
2022-69.8 M
2021-41.4 M
2020-37.6 M

About Abivax SA Financial Statements

Abivax SA investors use historical fundamental indicators, such as Abivax SA's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Abivax SA. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-158.6 M-150.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Abivax Stock Analysis

When running Abivax SA's price analysis, check to measure Abivax SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abivax SA is operating at the current time. Most of Abivax SA's value examination focuses on studying past and present price action to predict the probability of Abivax SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abivax SA's price. Additionally, you may evaluate how the addition of Abivax SA to your portfolios can decrease your overall portfolio volatility.